Perspective

Split Viewer

Blood Res 2014; 49(2):

Published online June 25, 2014

https://doi.org/10.5045/br.2014.49.2.77

© The Korean Society of Hematology

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism

Ho-Young Yhim, M.D. Ph.D.1,2, and Soo-Mee Bang, M.D. Ph.D.3

1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.

2Research Institute of Clinical Medicine, Chonbuk National University-Chonbuk National University Hospital, Jeonju, Korea.

3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table. 1.

Table 1 Proportion of cancer patients and eligibility criteria in major clinical trials regarding direct oral anticoagulants for the treatment of acute venous thromboembolism.


  1. Prandoni, P, Lensing, AW, Piccioli, A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 2002;100;3484-3488.
    Pubmed
  2. Wharin, C, Tagalakis, V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev, 2014;28;1-8.
    Pubmed
  3. Siegal, DM, Garcia, D. Anticoagulants in cancer. J Thromb Haemost, 2012;10;2230-2241.
    Pubmed
  4. Lee, AY, Levine, MN, Baker, RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med, 2003;349;146-153.
    Pubmed
  5. Schulman, S, Kearon, C, Kakkar, AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med, 2009;361;2342-2352.
    Pubmed
  6. Schulman, S, Kakkar, AK, Goldhaber, SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation, 2014;129;764-772.
    Pubmed
  7. Bauersachs, R, Berkowitz, SD, Brenner, B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010;363;2499-2510.
    Pubmed
  8. Buller, HR, Prins, MH, Lensin, AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012;366;1287-1297.
    Pubmed
  9. Agnelli, G, Buller, HR, Cohen, A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013;369;799-808.
    Pubmed
  10. Buller, HR, Decousus, H, Grosso, MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 2013;369;1406-1415.
    Pubmed
  11. Prins, MH, Lensing, AW, Bauersachs, R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J, 2013;11;21.
    Pubmed
  12. Raskob, GE, Buller, H, Angchaisuksiri, P, et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood, 2013;122;abst 211ASH Annual Meeting
  13. Schulman, S, Eriksson, H, Goldhaber, SZ, et al. Influence of active cancer on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: A pooled analysis from re-cover and re-cover II. Blood, 2013;122;abst 582ASH Annual Meeting

Article

Perspective

Blood Res 2014; 49(2): 77-79

Published online June 25, 2014 https://doi.org/10.5045/br.2014.49.2.77

Copyright © The Korean Society of Hematology.

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism

Ho-Young Yhim, M.D. Ph.D.1,2, and Soo-Mee Bang, M.D. Ph.D.3

1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.

2Research Institute of Clinical Medicine, Chonbuk National University-Chonbuk National University Hospital, Jeonju, Korea.

3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Table 1 . Proportion of cancer patients and eligibility criteria in major clinical trials regarding direct oral anticoagulants for the treatment of acute venous thromboembolism..


    References

    1. Prandoni, P, Lensing, AW, Piccioli, A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 2002;100;3484-3488.
      Pubmed
    2. Wharin, C, Tagalakis, V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev, 2014;28;1-8.
      Pubmed
    3. Siegal, DM, Garcia, D. Anticoagulants in cancer. J Thromb Haemost, 2012;10;2230-2241.
      Pubmed
    4. Lee, AY, Levine, MN, Baker, RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med, 2003;349;146-153.
      Pubmed
    5. Schulman, S, Kearon, C, Kakkar, AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med, 2009;361;2342-2352.
      Pubmed
    6. Schulman, S, Kakkar, AK, Goldhaber, SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation, 2014;129;764-772.
      Pubmed
    7. Bauersachs, R, Berkowitz, SD, Brenner, B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010;363;2499-2510.
      Pubmed
    8. Buller, HR, Prins, MH, Lensin, AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012;366;1287-1297.
      Pubmed
    9. Agnelli, G, Buller, HR, Cohen, A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013;369;799-808.
      Pubmed
    10. Buller, HR, Decousus, H, Grosso, MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 2013;369;1406-1415.
      Pubmed
    11. Prins, MH, Lensing, AW, Bauersachs, R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J, 2013;11;21.
      Pubmed
    12. Raskob, GE, Buller, H, Angchaisuksiri, P, et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood, 2013;122;abst 211ASH Annual Meeting
    13. Schulman, S, Eriksson, H, Goldhaber, SZ, et al. Influence of active cancer on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: A pooled analysis from re-cover and re-cover II. Blood, 2013;122;abst 582ASH Annual Meeting
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download